The Implementation of a Risk Stratification Tool for the Haematuria Clinic to Optimise the Management of Patients with High-Risk Bladder Cancer in the COVID-19 Era

Introduction: Elective waiting lists have become more stretched because of the COVID-19 pandemic and patients evidently been longer for treatment. Patients with high-risk bladder cancer require timely treatment there is strong evidence to suggest that delay in contributes a risk disease progression, metastases death. Studies shown tumour appearances at flexible cystoscopy (FC) can accurately predict on histopathology following transurethral resec-tion. An opportunity service improvement resulted review practice followed by authors development stratification tool haematuria clinic which aimed prioritise thepathway those disease.Materials methods: A was developed newly diagnosed tumours clinic. assessment carried out FC used disease, thus allowing be prioritised over low-risk list. It also includes reminder request staging investigations suspected disease. closed loop audit following: quality clinic; time from resection (TURBT); concordance between after TURBT; efficiency arranging early cancer; CT scan.
 Results: 93% second cycle compared 40% first cycle. Concordance noted 83% confirmed non-muscle invasive (NMIBC) muscle (MIBC) cycle, 100% NMIBC MIBC The interval TURBT decreased 27 days 21 NMIBC, 13 MIBC. Time 6 3 if made If scan requested later, increased 39 22 cycle.Conclusion: There high degree final pathol-ogy supported several series. Performing requesting minimise delays their pathway improve patient outcomes.